Lupin gets USFDA nod for Amlodipine Besylate tab

New Delhi, July 17 (UNI) Mumbai-based Lupin Ltd today announced that it has received approval from the USFDA for its Amlodipine Besylate Tablets variants of 2.5 mg, 5 mg and 10 mg.

Commercial shipments of Amlodipine Besylate Tablets will commence shortly, said a statement.

Lupin's Amlodipine Besylate Tablets are the AB-rated generic equivalent of Pfizer's Norvasc Tablets, a long-acting calcium channel blocker for the treatment of hypertension.

The brand product had annual sales of 2.7 billion dollars year ended December 2006, based on IMS Health sales data.

For the financial year ended March 2007, Lupin's Revenues and net were at Rs 20,289 million (475 million dollars) and Rs 3,021 million (70 million dollar) respectively.

UNI